LA JOLLA, CA – May 12, 2025 – A groundbreaking study from the Salk Institute has illuminated a previously underappreciated pathway critical for muscle health and energy metabolism, offering a new beacon of hope for millions grappling with debilitating fatigue and muscle weakness. Researchers have pinpointed estrogen-related receptors (ERRs) as indispensable drivers of mitochondrial growth and activity in muscle cells, suggesting that targeting these proteins could be a powerful new therapeutic strategy for a wide array of metabolic disorders and chronic diseases.
The findings, published today in the prestigious Proceedings of the National Academy of Sciences, reveal that ERRs, particularly the alpha subtype, play a pivotal role in boosting the cellular energy factories known as mitochondria. This discovery paves the way for the development of novel drugs designed to restore energy supplies in conditions ranging from muscular dystrophy and age-related muscle decline to the metabolic dysfunctions associated with cancer, multiple sclerosis (MS), heart disease, and dementia. For individuals unable to exercise due to illness or weakness, activating ERRs could mimic the beneficial effects of physical activity, offering a transformative approach to improving quality of life.
The Energy Crisis Within: Understanding Mitochondrial Dysfunction
Across the vast landscape of human biology, every single cell relies on tiny, bean-shaped organelles called mitochondria. Often dubbed the "powerhouses of the cell," these microscopic structures are responsible for converting the food we consume into adenosine triphosphate (ATP), the primary energy currency that fuels virtually all cellular processes. This intricate cellular-level metabolism is particularly vital in muscle cells, which demand enormous amounts of energy to facilitate everything from simple posture maintenance to strenuous physical exertion. Our ability to move, think, and even breathe is inextricably linked to the efficient functioning of these cellular engines.
However, this finely tuned system is remarkably vulnerable. It is estimated that 1 in 5,000 people are born with genetic defects that lead to dysfunctional mitochondria, resulting in severe metabolic disorders from birth. Beyond congenital conditions, a far greater number of individuals develop metabolic dysfunction later in life. This decline is a common and often debilitating hallmark of aging, contributing to the insidious onset of sarcopenia (age-related muscle loss) and general fatigue. Moreover, mitochondrial impairment is increasingly recognized as a significant contributor to the progression and severity of numerous chronic diseases, including various forms of cancer, the neurodegenerative challenges of multiple sclerosis, the widespread impact of heart disease, and the cognitive decline seen in dementia.
The current therapeutic landscape for mitochondrial dysfunction is notably challenging. Existing treatments often focus on managing symptoms rather than addressing the root cause of energy depletion. This difficulty stems from the complex and multifaceted nature of mitochondrial biology, as well as the diverse array of genetic and environmental factors that can lead to their malfunction. The urgent need for innovative and effective strategies to repair energy metabolism and combat muscle fatigue has driven researchers worldwide to explore new biological pathways that might offer a more direct and potent intervention. The Salk Institute’s latest research points to estrogen-related receptors as precisely such a pathway, offering a glimmer of hope where options have historically been scarce.
A Legacy of Discovery: Ronald Evans and Nuclear Hormone Receptors
The recent findings are not an isolated discovery but rather the culmination of decades of pioneering research led by Dr. Ronald Evans, a distinguished professor and the March of Dimes Chair in Molecular and Developmental Biology at the Salk Institute. Dr. Evans is a towering figure in molecular biology, renowned for his seminal contributions that have fundamentally reshaped our understanding of how hormones regulate gene expression and metabolism.
It was in the 1980s that Dr. Evans led the landmark discovery of a novel family of proteins he aptly named "nuclear hormone receptors." This groundbreaking work unveiled a sophisticated communication system within our cells, where these hormone-activated receptors act as master control switches. By attaching themselves directly to specific sequences of our DNA, nuclear hormone receptors dictate which genes get turned "on" or "off," thereby orchestrating a vast array of physiological processes, from development and reproduction to metabolism and inflammation. This discovery provided a molecular blueprint for understanding how hormones exert their profound effects on the body, opening up entirely new avenues for therapeutic intervention.
Among the many branches of this intricate nuclear hormone receptor family are the estrogen-related receptors (ERRs). As their name suggests, ERRs bear a structural resemblance to classic estrogen receptors, which are well-known for their roles in reproductive health and bone density. However, despite this superficial similarity, the precise functions and physiological significance of ERRs have, until now, remained far less understood.
"Estrogen-related receptors look a lot like classic estrogen receptors, but their function has been much less understood," explains Dr. Evans, reflecting on the historical context of his research. "Our lab discovered estrogen-related receptors in 1988 and was one of the first to recognize their role in energy metabolism. Now we’ve learned that estrogen-related receptors are indispensable drivers of mitochondrial growth and activity in our muscles. This makes them a really promising target to treat muscle weakness and fatigue in many different diseases that involve metabolic dysfunction."
Intriguingly, ERRs are often found in parts of the body that demand an exceptionally high amount of fuel to function optimally. Organs such as the heart and the brain, which are continuously active and metabolically demanding, exhibit high concentrations of these receptors. This observation naturally piqued the interest of Dr. Evans’s team, inspiring them to explore the potential role of ERRs in regulating metabolism within another notoriously high-energy organ system: skeletal muscle. This logical progression of inquiry ultimately laid the foundation for the current study, which has now definitively established the critical role of ERRs in maintaining muscle vitality and energy production.
Unlocking Muscle Power: The Role of Estrogen-Related Receptors
The fundamental requirement for muscles to generate force and enable movement necessitates a constant and robust supply of energy. This demand escalates dramatically during periods of physical activity. In fact, exercise is one of the most potent natural signals for muscle cells to initiate a process known as mitochondrial biogenesis. During biogenesis, a cell actively increases the number and even the size of its mitochondria, effectively expanding its internal "energy factory" capacity to produce more fuel. This adaptive response is what allows athletes to build endurance and strength, and it is a crucial mechanism for maintaining muscle health throughout life.
However, for millions of individuals suffering from muscular and metabolic disorders, or those weakened by aging or chronic illness, engaging in regular exercise is not just difficult; it’s often impossible. This creates a vicious cycle: low energy leads to inability to exercise, which further diminishes mitochondrial function and exacerbates fatigue. Recognizing this critical challenge, scientists have been intensely searching for alternative, pharmacological ways to stimulate mitochondrial biogenesis, hoping to provide the benefits of exercise without the physical exertion.
"Mitochondria are our cells’ energy factories, so the more we exercise, the more mitochondria our muscles need," says Weiwei Fan, the first author of the study and a staff scientist in Dr. Evans’s lab. "This got us thinking – if we could understand how exercise induces mitochondrial biogenesis, we might be able to target those same mechanisms pharmacologically to trigger this process in people who are too weak to exercise." This compelling question formed the central hypothesis guiding their ambitious research.
The Experimental Journey: Unraveling ERR Specificity
To systematically investigate whether estrogen-related receptors indeed played a significant role in muscle cell metabolism, Dr. Fan and his colleagues embarked on a meticulously designed experimental journey. Their approach involved genetically modifying mice to selectively delete different forms of these receptors in their muscle tissues. The three main forms of ERRs—alpha (ERRα), beta (ERRβ), and gamma (ERRγ)—were individually or combinatorially removed, allowing the researchers to observe the resulting effects on muscle physiology and mitochondrial function.
Their initial observations revealed a nuanced landscape of ERR distribution and function. They found that ERRα was by far the most abundant type of estrogen-related receptor in muscle tissue. Surprisingly, however, the loss of this single, most prevalent receptor alone had only "mild impacts" on muscle tissue under normal, sedentary conditions. This suggested a degree of functional redundancy or compensatory mechanisms at play. Further investigation into this puzzle led to another critical insight: the gamma receptor (ERRγ), though making up only a small fraction—approximately 4%—of the total estrogen-related receptors, demonstrated a remarkable capacity to compensate for the absence of ERRα under these baseline conditions. This highlights the intricate interplay and robust backup systems inherent in biological processes.
The true significance of ERRs became starkly evident when the researchers deleted both the alpha and gamma types simultaneously from the muscle cells of mice. This dual deletion resulted in "serious impairments in muscle mitochondrial activity, shape, and size." The mitochondria became less efficient, structurally compromised, and their overall capacity to generate energy was severely diminished. This crucial finding underscored that while individual ERRs might have some compensatory abilities, the collective presence of at least ERRα and ERRγ is essential for maintaining robust mitochondrial health and metabolic function in muscle.
Exercise, Adaptation, and the Indispensable ERRalpha
The persistent question remained: if ERRα is the most abundant, yet its singular deletion has only mild effects under normal conditions, what then is its primary purpose? The team hypothesized that the sheer "excess" of the alpha-type estrogen-related receptor was not mere biological redundancy but rather a strategic adaptation, specifically designed to help muscles respond and grow in response to the physiological demands of exercise.
To test this compelling hypothesis, the researchers introduced an exercise regimen for their genetically modified mice. The mice were allowed to exercise on mechanical wheels, providing a controlled and quantifiable stimulus for muscle activity. As expected, this exercise triggered a significant increase in mitochondrial biogenesis in wild-type (normal) mice, demonstrating the natural adaptive response of muscle to physical exertion. This experimental setup allowed the researchers to precisely assess whether ERRα was involved in this exercise-induced process.
The results were nothing short of revelatory. The experiment unequivocally demonstrated that losing ERRα alone—even with ERRγ still present—could entirely block exercise-induced mitochondrial biogenesis. This definitive finding firmly established ERRα as an indispensable component of the muscle’s adaptive response to exercise, solidifying its critical role in expanding the energy infrastructure necessary to meet increased demands.
Revisiting his earlier statement, Dr. Evans now emphasizes the full weight of this discovery: "Now we’ve learned that estrogen-related receptors are indispensable drivers of mitochondrial growth and activity in our muscles. This makes them a really promising target to treat muscle weakness and fatigue in many different diseases that involve metabolic dysfunction." The implications of this singular role for ERRα in exercise adaptation are profound, suggesting a direct molecular handle on a process that is vital for muscle health and overall vitality.
The Master Regulator and Its Partner: PGC1alpha and ERRalpha
The scientific community has long recognized another protein, PGC1α (Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha), as the "master regulator" of mitochondria throughout the body. Previous studies had established PGC1α’s central role in driving mitochondrial growth and function, particularly in response to exercise. However, PGC1α presents a significant challenge for therapeutic drug development. Unlike nuclear hormone receptors such as ERRs, PGC1α cannot bind directly to genes. Instead, it functions as a coactivator, meaning it must rely on partner proteins to physically interact with DNA and ultimately get the job done of turning genes "on" or "off." This indirect action makes PGC1α a more difficult and less direct target for pharmacological manipulation. Designing drugs to modulate a coactivator’s activity or its interactions with multiple partners is inherently more complex than targeting a protein that directly binds to DNA.
It was precisely this mechanistic challenge that led Dr. Evans’s lab to explore the possibility of a more direct pathway. When they meticulously examined the muscle cells after exercise, they uncovered a crucial piece of the puzzle: PGC1α was indeed partnering with ERRα to drive mitochondrial biogenesis. This discovery elegantly connected the previously known "master regulator" with the newly identified "indispensable driver."
Crucially, the Salk team found that, unlike PGC1α, ERRα possesses the remarkable ability to bind directly to mitochondrial energetic genes and activate them. This direct transcriptional control is a game-changer for drug development. The capacity of ERRα to act as a direct switch for mitochondrial performance makes it an exceptionally promising target for therapeutic intervention. By identifying and activating ERRα, scientists could potentially bypass the complexities of PGC1α’s indirect mechanisms, offering a more straightforward and potent way to improve muscle’s mitochondrial performance and energy output. This direct binding capability positions ERRα as a highly attractive candidate for developing drugs that can robustly and efficiently boost cellular energy production.
Far-Reaching Implications: A New Dawn for Metabolic Health
The discovery of estrogen-related receptors, particularly ERRα, as indispensable drivers of mitochondrial growth and activity in muscles, carries far-reaching implications for human health. The potential therapeutic applications extend well beyond just treating muscle weakness and fatigue, promising a new dawn for addressing a wide spectrum of metabolic health challenges.
"Our findings suggest that activating estrogen-related receptors could not only help fuel people’s muscles, but it could also have other beneficial effects across the whole body," emphasizes Weiwei Fan. "Improving mitochondrial function and energy metabolism could help strengthen many different organ systems, including the brain and heart." This holistic perspective underscores the systemic impact of enhanced energy metabolism.
The most immediate and direct impact of this research is on conditions characterized by muscle weakness and fatigue. For individuals living with muscular dystrophy, where progressive muscle degeneration leads to severe weakness, activating ERRs could potentially slow disease progression and enhance remaining muscle function. Similarly, for the millions experiencing age-related muscle decline (sarcopenia) and general fatigue that often accompanies aging, an ERR-targeting drug could act as a metabolic booster, helping to maintain strength, mobility, and vitality into older age. Patients suffering from chronic fatigue syndromes, whose lives are severely impacted by persistent, unexplained exhaustion, could find significant relief through interventions that directly address underlying energy deficits.
Beyond muscle-specific ailments, the systemic benefits are profound. Improving mitochondrial function in muscle has ripple effects throughout the body, particularly in other metabolically demanding organs:
- Neurodegenerative Diseases: Conditions like multiple sclerosis (MS), Alzheimer’s disease, and other forms of dementia are increasingly linked to mitochondrial dysfunction and energy deficits in brain cells. Enhancing mitochondrial performance via ERR activation could protect neurons, improve cognitive function, and potentially slow disease progression in the central nervous system.
- Cardiovascular Disease: The heart is one of the most energy-intensive organs in the body. Mitochondrial dysfunction plays a crucial role in heart failure and other cardiovascular pathologies. Boosting cardiac mitochondrial health through ERR activation could improve heart muscle function, enhance pumping efficiency, and offer new strategies for preventing and treating heart disease.
- Cancer: Cancer cells often exhibit altered metabolism, known as the Warburg effect, where they rely more on glycolysis even in the presence of oxygen. Modulating mitochondrial function via ERRs could potentially disrupt these metabolic adaptations in cancer cells, opening new avenues for cancer therapy by targeting their energy supply.
- Metabolic Syndrome and Type 2 Diabetes: Dysfunctional mitochondria contribute to insulin resistance and impaired glucose metabolism. By improving mitochondrial efficiency, ERR activators could help to restore metabolic balance, making them potential candidates for treating and preventing type 2 diabetes and related metabolic disorders.
In essence, the Salk Institute’s findings lay the groundwork for developing what could be termed a "metabolic mimetic" or "exercise mimetic"—a pharmacological intervention that confers many of the beneficial effects of physical exercise on mitochondrial health, but without requiring the physical exertion itself. This would be a game-changer for countless individuals currently limited by their physical capabilities, offering a new pathway to reclaim energy, strength, and overall well-being.
The Road Ahead: Challenges and Future Directions
While the discovery of estrogen-related receptors as key regulators of muscle metabolism represents a significant scientific leap, the journey from laboratory breakthrough to approved human therapy is often long and complex. Several challenges and exciting avenues for future research lie ahead.
One primary challenge will be in the drug development process itself. Scientists will need to design molecules that can selectively activate ERRs, particularly ERRα, without triggering unwanted side effects. Given the "estrogen-related" nomenclature, a critical consideration will be to develop compounds that are highly specific to ERRs and do not activate classic estrogen receptors, which could lead to hormonal imbalances or other undesirable effects. This will require sophisticated medicinal chemistry to fine-tune the specificity and potency of potential drug candidates.
Further research will also delve deeper into the specificity and interplay between the different ERR subtypes. While ERRα has been identified as the indispensable driver in exercise-induced biogenesis, the compensatory role of ERRγ under normal conditions, and the function of ERRβ, warrant more detailed investigation. Understanding the nuanced roles of each receptor and how they interact could lead to even more targeted and effective therapeutic strategies. For instance, developing drugs that selectively activate only ERRα or a specific combination of ERRs might offer superior therapeutic profiles.
The path forward will involve extensive preclinical testing to ensure the safety and efficacy of any ERR-targeting compounds. This will include rigorous studies in animal models to assess their impact on various organ systems and to identify any potential toxicities. If successful, these compounds would then move into clinical trials in humans, a multi-phase process that typically spans many years and requires substantial investment. The goal would be to demonstrate not only that the drugs are safe but also that they effectively improve mitochondrial function, muscle strength, and reduce fatigue in patients with metabolic disorders.
Beyond direct drug development, future research will continue to explore the function and regulation of ERRs in other vital organs beyond muscle, such as the brain, heart, liver, and kidneys. Understanding how ERR activity can be modulated in these tissues could unlock even broader therapeutic applications for diseases affecting these systems. The concept of personalized medicine will also be relevant, as researchers investigate how different genetic backgrounds and disease states might influence an individual’s response to ERR activation.
The collaborative nature of this work, involving researchers from the Salk Institute, the University of Oklahoma, and the University of Sydney, Australia, highlights the power of inter-institutional cooperation in tackling complex biological questions. The extensive financial support from organizations such as the National Institutes of Health, the Department of the Navy, the Larry L. Hillblom Foundation, the Wu Tsai Human Performance Alliance, the Henry L. Guenther Foundation, and the Waitt Foundation underscores the significant investment and belief in the potential of this line of inquiry. These partnerships and funding mechanisms will be crucial in driving the research forward.
Conclusion: A Glimmer of Hope for Millions
The Salk Institute’s latest research on estrogen-related receptors represents a truly exciting and transformative advancement in our understanding of cellular energy metabolism. By identifying ERRs, particularly ERRα, as the indispensable molecular switches that regulate mitochondrial growth and activity in muscles, scientists have uncovered a direct and powerful therapeutic target. This discovery moves beyond merely managing symptoms, offering a novel strategy to address the fundamental energy deficits that underpin a vast array of debilitating conditions.
For millions worldwide who suffer from muscle weakness, chronic fatigue, and the metabolic complications of aging and diseases like muscular dystrophy, MS, heart disease, and dementia, these findings offer a profound glimmer of hope. The prospect of developing a drug that can pharmacologically stimulate mitochondrial biogenesis, effectively mimicking the beneficial effects of exercise, holds the potential to dramatically improve quality of life, restore vitality, and redefine the treatment landscape for metabolic disorders. As researchers continue to unravel the intricacies of ERR function and regulation, the promise of more energetic and resilient lives for countless individuals moves ever closer to reality.
About the Author
